Vaccinex Announces Publication of Results From a Phase I Trial of Anti-Semaphorin 4D Antibody, VX15/2503, in Patients With Advanced Solid Tumors

Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, today announced publication of a manuscript entitled "Safety, Pharmacokinetics and Pharmacodynamics of a Humanized anti-Semaphorin 4D Antibody in a First-In-Human Study of Patients with Advanced Solid Tumors" in…Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, today announced publication of a manuscript entitled "Safety, Pharmacokinetics and Pharmacodynamics of a Humanized anti-Semaphorin 4D Antibody in a First-In-Human Study of Patients with Advanced Solid Tumors" in the journal Clinical Cancer Research (2015 Oct 7). The antibody, termed VX15/2503, was found to be well tolerated in this patient population and conformed to expected PD profile. In addition, one patient exhibited a partial response, 45% of patients had stable disease for at least 8 weeks and 19% were found to have stable disease for at least 16 weeks. Vaccinex is actively planning follow-on studies of combination therapy of VX15/2503 with a checkpoint inhibitor in selected cancer indications which they intend to initiate in 1H 2016. "In prior preclinical studies, the combination of anti-semaphorin 4D antibody with a checkpoint inhibitor has been shown to strikingly eradicate tumors. The importance of the safety profile reported in the present study is that it strongly supports continued development of this novel combination therapy as a potentially promising cancer treatment. We look forward to initiating a phase